Maarten Hoek
Senior Vice President & Head of Research Maze Therapeutics
Seminars
Monday 16th March 2026
Panel Discussion: Novel Delivery Modalities & Gene Therapy Approaches in PKD
2:00 pm
- Exploring gene therapy, antisense oligonucleotides, and CRISPR-based approaches
- Overcoming delivery barriers to the kidney
- Designing preclinical studies with translational relevance
- Regulatory considerations for first-in-human studies
Wednesday 18th March 2026
Leveraging Human Genetics to Advance Precision Medicine in CKD: Translating APOL1 & Amino Acid Transporter Insights into Clinical Progress
1:30 pm
- Defining distinct CKD-susceptible populations through APOL1 genetic variants and exploring the potential to modulate this biology with a small-molecule inhibitor supported by favorable Phase 1 safety and pharmacokinetic results
- Interrogating the genetic and biological role of the amino acid transporter BoAT1 (SLC6A19) in CKD progression to uncover new opportunities for therapeutic intervention beyond current standard-of-care approaches
- Presenting Phase 1 clinical data and mechanistic hypotheses linking target modulation to improved kidney outcomes
- Leveraging human genetics and biomarker datasets to validate target inhibition, confirm efficacy signals, and enable precision-driven clinical development in CKD populations
